Capecitabine in the management of colorectal cancer.
Significant progress has been made in the chemotherapy of colorectal cancer. The author discusses new available options and the development of a new oral fluoropyrimidine, capecitabine (Xeloda). The rational development of this targeted drug with its selective activation in tumor tissue is highlighted. The clinical development of capecitabine and its present and future role in the management of colorectal cancer are reviewed.
Ottawa Regional Cancer Centre, 503 Smyth Rd., Ottawa, ON K1H 1C4, Canada. Jean.maroun@orcc.on.ca
J A
JA
Maroun
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000069287:Capecitabine; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil